Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $500.00.

Patrick Trucchio’s rating is based on Alnylam Pharma’s strong execution and innovation in the ATTR-CM space, particularly with the successful launch of AMVUTTRA (vutrisiran) for ATTR amyloidosis with cardiomyopathy. The company’s strategic initiatives, including the anticipated pivotal readout from zilebesiran’s Phase 2 KARDIA-3 study and the commencement of the Phase 3 TRITON-CM trial for nucresiran, are contributing to a solid momentum.
Additionally, Alnylam’s robust pipeline, which includes late-stage programs for CNS, cardiometabolic diseases, and bleeding disorders, is advancing well. The company’s strong commercial execution, supported by favorable formulary access and payer coverage, is expected to drive sustained double-digit revenue growth. Trucchio remains confident in the long-term potential of Alnylam’s TTR franchise to exceed $10 billion in annual revenue.

In another report released on May 30, RBC Capital also maintained a Buy rating on the stock with a $330.00 price target.

Based on the recent corporate insider activity of 90 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.